Changes of peripheral blood lymphocyte subsets in a long-term survivor with advanced renal cell carcinoma

1997 ◽  
Vol 2 (2) ◽  
pp. 129-132
Author(s):  
Koji Yoshimura ◽  
Tamio Yamauchi ◽  
Hiroshi Maeda ◽  
Tsuneo Kawai
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Renal Cell ◽  
Blood Lymphocyte ◽  
Lymphocyte Subsets ◽  
Advanced Renal Cell Carcinoma ◽  
Term Survivor

Prognostic Factors of Peripheral Blood Lymphocyte Subsets in Patients with Renal Cell Carcinoma

1996 ◽  
Vol 57 (1) ◽  
pp. 5-10 ◽  
Author(s):  
Kiminobu Arima ◽  
Masateru Nakagawa ◽  
Makoto Yanagawa ◽  
Yoshiki Sugimura ◽  
Hiromi Tochigi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Renal Cell ◽  
Blood Lymphocyte ◽  
Lymphocyte Subsets

The peripheral blood inflammatory markers may predict response to nivolumab for advanced renal cell carcinoma

2019 ◽  
Vol 18 (1) ◽  
pp. e2094-e2095
Author(s):  
D. Ikarashi ◽  
R. Kato ◽  
Y. Kato ◽  
M. Kanehira ◽  
R. Takata ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Peripheral Blood ◽  
Renal Cell ◽  
Inflammatory Markers ◽  
Advanced Renal Cell Carcinoma

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

1993 ◽  
Vol 11 (7) ◽  
pp. 1368-1375 ◽  
Author(s):  
L M Minasian ◽  
R J Motzer ◽  
L Gluck ◽  
M Mazumdar ◽  
V Vlamis ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Interferon Alfa ◽  
Advanced Renal Cell Carcinoma ◽  
Survival Duration

PURPOSE Three trials were conducted to define the efficacy and toxicity of interferon alfa-2a in the treatment of metastatic renal cell cancer. Univariate and multivariate analyses were performed to identify prognostic factors for survival. PATIENTS AND METHODS Prospectively, 159 patients were treated with interferon alfa-2a. In the first trial, 42 patients received 50 x 10(6) U/m2 intramuscularly three times per week. In the second trial, 64 patients received gradually escalating doses of interferon alfa-2a from 3 to 36 x 10(6) U subcutaneously administered daily. The third trial was randomized; 25 patients received daily interferon alfa-2a alone and 28 were treated with daily interferon alfa-2a and 0.15 mg/kg vinblastine every 3 weeks. RESULTS The overall response proportion was 10% (two complete and 14 partial responses). The median response duration was 12.2 months. The median survival duration was 11.4 months, with 3% of patients alive at 5 or more years. A univariate statistical analysis showed that a Karnofsky performance status > or = 80, prior nephrectomy, and interval from diagnosis to treatment of longer than 365 days were significant prognostic factors for survival. In a multivariate analysis, only prior nephrectomy and Karnofsky performance status > or = 80 were shown to be independent predictors of survival. CONCLUSION Interferon alfa-2a had minimal antitumor activity in patients with advanced renal cell carcinoma and long-term survival was achieved in a small proportion of patients. The need for continued investigation and the identification of more effective therapy for advanced renal cell carcinoma is evident from the poor overall survival rate observed in these 159 patients. The investigation of new agents and of interferon alfa-2a in combination with other agents remains a priority.

scholarly journals Long-Term Safety with Axitinib in Advanced Renal Cell Carcinoma

2014 ◽  
Vol 25 ◽  
pp. iv293
Author(s):  
S. Hariharan ◽  
W.G. Roberts ◽  
Z. Askerova ◽  
B. Escudier ◽  
J. Tarazi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document